U.S. markets open in 6 hours 17 minutes

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.6200-0.0100 (-0.22%)
At close: 4:00PM EDT

ARCA biopharma, Inc.

11080 CirclePoint Road
Suite 140
Westminster, CO 80020
United States
720 940 2200
http://arcabio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael R. BristowCo-Founder, Pres, CEO & Director296.15kN/A1945
Mr. Thomas A. KeuerChief Operating Officer304.02kN/A1959
Mr. Christopher D. OzeroffSr. VP, Gen. Counsel & Sec.290.16kN/A1959
Mr. Brian L. SelbyChief Accounting Officer & VP of Fin.N/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Corporate Governance

ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.